← Oncology Approval Tracker

FDA DECISION ·

Romidepsin injection

romidepsin · Teva Pharmaceuticals USA

FDA approvalNew formulationCutaneous T-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with cutaneous T-cell lymphoma who had received at least one systemic therapy.

LAMPGEN ANALYSIS

Why it matters

Added a liquid injectable formulation of an established histone deacetylase inhibitor for previously treated cutaneous disease.

What research teams should watch

Use solution-specific dilution instructions and confirm the qualifying prior systemic regimen.

PRIMARY RECORDS

Sources